Don't know why I'm posting this...... I think that it's bull, that the company has no plans to commercialize this product. Prove me wrong, slime ball Rosenwaldites! Let's see a Paramount/Aries company produce something other than the usual BS and bait and switch insider wealth.
VimRx, aka Nexell..........
finance.yahoo.com
finance.yahoo.com
sec.gov
Market cap of $50M (down from about $2 billion split and dilution adjusted), how much did Rosenwald take out en route? When did he sell? And, it's not even that simple, as VimRx actually purchased other Rosenwald companies along the way. Study the Nexcell subsidiaries! It's all a big game..... keep the company alive, make it look "real", keep fleecing the public at every op, take your money out when you can, and sell a company into the primary play when convenient.
sec.gov
sec.gov
sec.gov
Study Genta!! We let these guys get away with this crap, time after time. Nobody does anything to stop it!
Come on, Spana, prove that you're not just another Rosenwaldite. Build a *real* business, target *real* therapeutics, diagnostics and diseases!
Monday June 25, 7:33 am Eastern Time
Press Release
Palatin Technologies Presents LeuTech Phase 2
Results For Imaging Osteomyelitis At The Society Of
Nuclear Medicine Annual Meeting
PRINCETON, N.J.--(BUSINESS WIRE)--June 25, 2001--Palatin Technologies, Inc.
(AMEX: PTN - news) announced today that positive interim results from a Phase 2 clinical
trial of LeuTech(TM) in patients with osteomyelitis (bone infection) were presented
yesterday at the Society of Nuclear Medicine (SNM) annual meeting in Toronto, Canada.
The presentation, by lead investigator Christopher J. Palestro, MD from Long Island Jewish
Medical Center, New Hyde Park, NY, summarized results from an ongoing study
demonstrating the ability of LeuTech to rapidly and accurately detect osteomyelitis in diabetic
patients with pedal (foot) ulcers.
The objectives of the study were to evaluate the safety and utility of LeuTech(TM) for
diagnosing osteomyelitis and to compare LeuTech(TM) to both Indium oxine-labeled white
blood cells and 3-phase bone scan, the current standard-of-care for diagnosing osteomyelitis
in these patients. The results, encompass data from 19 patients, and show LeuTech(TM) to
be well tolerated and superior to both Indium oxine-labeled white blood cells and 3-phase
bone scan. In all cases, LeuTech produced a diagnostic image in less than 1 hour; compared
to the 24 hours required for a diagnostic image when using Indium oxine-labeled white blood
cells.
``We are very encouraged by our experience with LeuTech to date, compared to existing
diagnostic methods, this trial suggests that LeuTech(TM) may provide a simpler, more rapid
means of diagnosing serious bone infections in diabetic patients and other patients at risk. We
look forward to validating these results in a larger number of patients.'' said Dr. Palestro.
Carl Spana, Ph.D., President & Chief Executive Officer of Palatin said, ``We continue to be
extremely excited about LeuTech's performance. LeuTech(TM) generates high quality
diagnostic images in less then 1 hour. The quality, speed and ease of use of LeuTech
represent key advantages over Indium oxine-labeled white blood cells. These advantages
suggest that LeuTech has the potential to become the standard of care for imaging sites of
infection.''
``We continue to make significant progress toward resolving all outstanding manufacturing issues regarding LeuTech(TM), to
clear the way for final regulatory approval of the product,'' Dr. Spana also noted.
LeuTech(TM) is a radiolabled monoclonal antibody that is intended to image and diagnose sites of infection. When injected into
the blood stream, LeuTech(TM) binds to white blood cells present at the infection site and labels these cells with radioactivity,
enabling the infection sites to be readily detected. On July 10, 2000, the United States Food & Drug Administration (FDA)
Medical Imaging Drugs Advisory Committee (MIDAC) unanimously recommended the approval of LeuTech(TM) for use in
diagnosing appendicitis in patients with equivocal signs and symptoms. On September 28, 2000 Palatin received a complete
review Letter from the FDA related to its Biologics License Application (BLA) for LeuTech(TM). No further data was
requested on the Company's clinical efficacy and safety data. However, certain manufacturing, quality control and process
validation steps and data were requested by the FDA prior to approval. Palatin anticipates the completion of the appropriate
steps resulting in the filing of amendments to the BLA with the FDA to be finalized in the second half of 2002.
Palatin Technologies, Inc. is a development-stage biopharmaceutical company with pharmaceutical products in development
using its enabling peptide platform technology, MIDAS. The Company is developing LeuTech(TM), a product for infection
imaging based on its proprietary radiolabeled monoclonal antibody. For further information visit the Palatin web site at
www.palatin.com.
Statements about the Company's future expectations, including development and regulatory plans, and all other statements in
this document other than historical facts, are ``forward-looking statements'' within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation
Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created
thereby.
Palatin's actual results may differ materially from its historical results of operations and those discussed in the forward-looking
statements for various reasons, including, but not limited to the Company's ability to carry out its business plan, successful
development and commercial acceptance of its products, ability to fund development of technology, the risk that products may
not result from development activities, protection of its intellectual property, ability to establish and successfully complete clinical
trials for product approval, need for regulatory approvals, dependence on it partners for development of certain projects, and
other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not
responsible for events not updated after the date on this press release.
Contact:
Palatin Technologies, Inc.
Carl Spana, Ph.D.
609/520-1911
cspana@palatin.com
or
Stephen T. Wills, CPA, MST
609/520-1911
swills@palatin.com
or
Kureczka/Martin Associates (Media)
Joan Kureczka, 415/821-2413
Ellen Martin, 510/832-2044
Jkureczka@aol.com |
